<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815473</url>
  </required_header>
  <id_info>
    <org_study_id>VSP-001</org_study_id>
    <nct_id>NCT04815473</nct_id>
  </id_info>
  <brief_title>AndraValvulotome Post-Market Study</brief_title>
  <official_title>AndraValvulotome Post-Market Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andramed GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andramed GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AndraValvulotome Post-Market Study is a prospective, open-label, multi-center study to&#xD;
      evaluate the efficacy and safety of the AndraValvulotome. A maximum of 70 patients will be&#xD;
      enrolled with peripheral artery disease (PAD) in up to 10 sites. Study participants will be&#xD;
      primarily observed during the bypass procedure. In addition, the patients will be&#xD;
      re-evaluated at the follow-up visit which will be scheduled 30 +/- 7 days after beginning of&#xD;
      the study participation.&#xD;
&#xD;
      The objective of this study is to analyze the efficacy and safety of the valvulotomy of the&#xD;
      venous valves with the CE marked AndraValvulotome during the bypass procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of device related serious adverse events (SAE)</measure>
    <time_frame>until 30 +/- 7 days follow-up visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of not sufficiently incised venous valves</measure>
    <time_frame>Until approximately 10 days after procedure or discharge</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulsatile blood flow</measure>
    <time_frame>during procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of device related bleeding</measure>
    <time_frame>until 30 +/- 7 days follow-up visit</time_frame>
    <description>A device related bleeding could occur due to the application of the device. Bleeding is defined as a decrease of a value of 2 hemoglobin points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of device related bleeding</measure>
    <time_frame>until 30 +/- 7 days follow-up visit</time_frame>
    <description>A device related bleeding could occur due to the application of the device. Bleeding is defined as a decrease of a value of 2 hemoglobin points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of device related AE and SAE</measure>
    <time_frame>until 30 +/- 7 days follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of device related AE and SAE</measure>
    <time_frame>until 30 +/- 7 days follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of passages of valvulotomy</measure>
    <time_frame>during procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency rate</measure>
    <time_frame>until 30 +/- 7 days follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary technical success</measure>
    <time_frame>Until approximately 10 days after procedure or discharge</time_frame>
    <description>technical success is defined as clinical efficacy after valvulotomy without the presence of device related AE and SAE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Patients treated with AndraValvulotome</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Valvulotomy</intervention_name>
    <description>Valvulotomy of the venous valves</description>
    <arm_group_label>Patients treated with AndraValvulotome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with peripheral arterial disease who are planned to undergo a bypass surgery&#xD;
             with autologous vena saphena magna and using a valvulotome.&#xD;
&#xD;
          -  Patient has to be consented and a informed consent form needs to be signed.&#xD;
&#xD;
          -  Patient is able to and willing to participate in the 30 days follow-up.&#xD;
&#xD;
          -  Vein diameter is at least 2mm (4F system) and 3mm (5F system).&#xD;
&#xD;
          -  Vein diameter does not exceed 8mm (OTW-version) or 6mm (TIP-version)&#xD;
&#xD;
          -  Bypass needs to be a continuous vena saphena magna with a length of at least 20cm.&#xD;
&#xD;
          -  Rutherford category III - V&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have not completed 18 years of age&#xD;
&#xD;
          -  Patients who are pregnant or assuming to be pregnant, and breast feeding.&#xD;
&#xD;
          -  Patients who cannot participate due to medical or physical condition based on the&#xD;
             decision of the physician.&#xD;
&#xD;
          -  Life expectancy less than 1 year&#xD;
&#xD;
          -  Known allergies to materials of the tip, cutting basket, outer catheter, kink&#xD;
             protection and braid.&#xD;
&#xD;
          -  Rutherford category 0-2, and 6&#xD;
&#xD;
          -  Using varicose vein&#xD;
&#xD;
          -  Exclusion criteria based on IFU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Hyhlik-DÃ¼rr, MD</last_name>
    <phone>0049821 400 161763</phone>
    <email>Alexander.Hyhlik-Duerr@uk-augsburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hubertus</name>
      <address>
        <city>Berlin</city>
        <zip>14129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernst Weigang, MD</last_name>
      <phone>004903081008125</phone>
      <email>ernst.weigang@jsd.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

